Pulse Biosciences

181 articles about Pulse Biosciences

• Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results

  3/28/2024

  Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2023.

• Pulse Biosciences Announces Plans to Initiate a Rights Offering

  3/28/2024

  Pulse Biosciences, Inc., a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ technology, announced that its Board of Directors has unanimously approved plans to initiate a rights offering.

• Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024

  3/14/2024

  Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, March 28, 2024.

• Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study

  2/14/2024

  Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX ® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study.

• Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium

  1/31/2024

  Pulse Biosciences, Inc. (Nasdaq: PLSE) today announced that its nsPFA technology will be featured in a podium presentation at the 29th Annual AF Symposium in Boston, Massachusetts, on February 2, 2024 at 10:00am ET.

• Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp

  1/2/2024

  Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the filing of a premarket notification 510(k) to the U.S. Food and Drug Administration (FDA) for its novel CellFX nsPFA Cardiac Clamp.

• Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter

  12/20/2023

  Pulse Biosciences, Inc. today announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter.

• Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode

  11/21/2023

  Pulse Biosciences, Inc. today announced the filing of a premarket notification 510(k) to the U.S. Food and Drug Administration (FDA) for its novel CellFX nsPFA percutaneous electrode.

• Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

  11/15/2023

  Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced plans to present at the upcoming 35th Annual Piper Sandler Healthcare Conference in New York.

• Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results

  11/13/2023

  Pulse Biosciences will host Third Quarter 2023 Financial Results conference call at 9:00 am PT / 12:00 pm ET on Monday, November 13, 2023.

• UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call

  11/10/2023

  Pulse Biosciences, Inc., a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation technology for the treatment of atrial fibrillation, announced it will now report financial results for the third quarter of 2023 before market opens on Monday, November 13, 2023.

• Pulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 2023

  10/30/2023

  Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced it will report financial results for the third quarter of 2023 after market close on Monday, November 13, 2023.

• Pulse Biosciences Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

  10/24/2023

  Pulse Biosciences, Inc. today announced the appointment of Niv Ad, M.D. as Chief Science Officer, Cardiac Surgery.

• Pulse Biosciences Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study

  10/2/2023

  Pulse Biosciences, Inc. today announced a collaboration with CardioNXT, to support Pulse Biosciences’ planned nsPFA cardiac catheter first-in-human study focused on the treatment of atrial fibrillation.

• Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Circumferential Catheter System to be Featured in a Presentation at the Global EP Summit

  9/29/2023

  Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced its nsPFA technology will be featured in a presentation at the Global EP Summit 2023 in Cleveland, OH from September 29th to 30th, 2023.

• Pulse Biosciences’ First Study in a Surgical Application of Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Two Poster Presentations at the American Thyroid Association Annual Meeting

  9/27/2023

  Pulse Biosciences, Inc. today announced its nsPFA technology will be featured in two poster presentations at the upcoming American Thyroid Association 2023 Annual Meeting in Washington D.C. from September 27th to October 1st, 2023.

• Pulse Biosciences to Present at Gilmartin Group Emerging Growth Showcase

  9/7/2023

  Pulse Biosciences, Inc. today announced plans to participate at the upcoming Gilmartin Group Emerging Growth Showcase, taking place virtually.

• Pulse Biosciences Clarifies Details of Recent S-3 Filing

  8/24/2023

  Pulse Biosciences, Inc. provided additional clarification regarding the details of the SEC form S-3 filed August 11, 2023.

• Pulse Biosciences Reports Business Updates and Second Quarter 2023 Financial Results

  8/10/2023

  Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced financial results for the second quarter ended June 30, 2023.

• Pulse Biosciences Schedules Second Quarter 2023 Financial Results Conference Call for August 10, 2023

  7/27/2023

  Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, announced today it will report financial results for the second quarter of 2023 after market close on Thursday, August 10, 2023.